Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Health system analysis to support capacity development to respond to pandemic influenza in Asia (ASIAFLUCAP)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Germany,Netherlands,Indonesia,Viet Nam,Thailand,Taiwan, Province of China
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-05-01
End date: 2011-04-30
Duration (months): 36.0
Total project cost (EUR): 3402209.0
EU funding (EUR): 2599997.0
Participants: 7
Project status: CLOSED

Operational planning to implement strategic pandemic influenza plans remains a major challenge. This project will help ensure resources are deployed effectively and efficiently in countries in Asia in the event of a pandemic. To date, an important challenge has been that there is no universally accepted, organised method for evaluating preparedness. This research proposal builds upon and extends an innovative pilot research project between collaborators being conducted in Thailand linking coherently quantitative analyses of resource gaps with qualitative assessments of governance constraints given different epidemiological scenarios. The goal of the project is to provide a framework to evaluate health system operational capacity and, in 4 settings (Vietnam, Indonesia, Thailand, Taiwan), and systematically determine operational capacity gaps in order support containment and mitigation of pandemic influenza. Operational capacity gaps will be determined under 4 hypothetical pandemic scenarios. Resources available will be determined in order to address containment and mitigation outcomes. Resources will be mapped at 2 levels (the enabling environment and the organisational environment tasked with implementation). Governance arrangements will be evaluated according to the same pandemic influenza scenarios. The same scenarios will be drawn upon in evaluations of each setting to ensure lessons learned are coherent. With ministerial support across sites, the results from this work will inform revisions of strategic and operational pandemic influenza plans, provide a critical resource for the ‘war room’ in the event of a pandemic, and inform decisions about future resource allocation.

Keywords: preparedness,avian influenza,pandemic,health systems,contingency,asia,response,h5n1
Functional optical coherence tomography (FUN OCT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Denmark,Germany,United Kingdom,Germany,Austria,Austria,Germany
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-04-01
End date: 2012-09-30
Duration (months): 54.0
Total project cost (EUR): 7088472.6
EU funding (EUR): 5411719.0
Participants: 7
Project status: CLOSED

The aim of FUN OCT is to expand the non-invasive optical biopsy capability of optical coherence tomography (OCT) and combination of OCT with multiphoton tomography (MT) to develop novel functional capabilities hereby enabling ‘morphofunctional’ performance, i.e., the fusion of anatomic and functional imaging at the cellular resolution level. These methodologies will enable unprecedented non-invasive detection of depth resolved physiological, metabolic as well as molecular specific tissue information, i.e., forming a novel, powerful medical imaging platform. This novel platform fills an important gap left by today’s medical imaging technology. The hypothesis is that the combination of cellular resolution, real time imaging of morphology and depth resolved tissue function could enable a major step forward in early cancer diagnosis and in the early detection of retinal pathologies that are world wide leading causes of blindness. This is accomplished due to a synergistic effect from joining complementary international expertise in the fields of laser sources, OCT, MT and beam delivery system technology. The consortium comprises 6 research groups and 2 SMEs. The consortium will make use of its existing relations to clinical collaborators in order to achieve proof-of-principle validation of the imaging modalities. The outcome contributes directly to improving and to maintaining the quality of life and living conditions of the European aging population through early diagnosis of cancer and of retinal pathologies as well as more efficient therapy monitoring. Moreover, the envisaged imaging modality may in the long term act as a screening device to investigate the prevalence of cancer as a function of geographic (regional) or gender related parameters. Finally, the diagnosis of other age-related diseases in a variety of medical fields, such as cardiology, neurology, gynaecology, and gastroenterology, benefit from this novel diagnostic platform provided by FUN OCT.

Keywords: functional optical coherence tomography,optical coherence microscopy,spectroscopic oct,optophysiology,doppler oct,polarisation-sensitive oct,multiphoton tomography,cancer,ophthalmoly
Identifying novel regulatory mechanisms of miRNA functions (MIREG)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Molecular and Structural Biology and Biochemistry
Countries involved: Netherlands
Call:  (ERC-2007-StG, 2007)
Start date: 2008-10-01
End date: 2013-09-30
Duration (months): 60.0
Total project cost (EUR): 1349760.0
EU funding (EUR): 1349760.0
Participants: 1
Project status: CLOSED

microRNAs (miRNAs) are master regulators of gene expression capable of defining and altering cell identity. Because of their potency, small size, simple mode of action (target recognition through a Watson-Crick type of base pairing) and the possibility to inhibit them in vivo, miRNAs are valuable therapeutic targets. Recently, we have used novel functional-genetic screening approaches and identified the miR-372, 373 and 520, as well as the miR-221&222 family as cancerous miRNAs. These miRNAs are oncogenes, as they are deregulated in specific types of cancers, target tumor suppressors and their inhibition reverts cancerous phenotypes. However, at present almost nothing is known about the mechanisms governing the expression and function of these, as well as many other, oncogenic miRNAs. Here, I propose experiments to identify and characterize factors affecting the activity of oncogenic miRNAs using an array of molecular and genetic tools. Our preliminary results indicate the existence of novel regulators and mechanisms of miRNA activity. We therefore believe that the information collected here not only will lead to a better understanding of miRNA functions, but will also identify novel modes of manipulating miRNA activity in human disease.

Keywords: micrornas,rna binding protein,screen,genetic,development
Portable automated test for fast detection and surveillance of influenza (PORTFASTFLU)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,France,Belgium,Spain,Spain,United Kingdom,Ireland,United Kingdom
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-01-01
End date: 2010-12-31
Duration (months): 36.0
Total project cost (EUR): 3933101.0
EU funding (EUR): 2965874.0
Participants: 9
Project status: CLOSED

The PORTFASTFLU’s objective is to develop and validate a rapid diagnostic test for influenza that will be used as point-of-care systems in developed and developing countries. Experts and international bodies agree that the rapid detection of influenza is vital in combating this major threat to human health. Nucleic acid analysis is the most appropriate assay scheme for both early detection and late surveillance of influenza, and is routinely used by WHO and OIE virology reference laboratories. PORTFASTFLU&apos;s consortium aims at developing and validating a Point of Care (POC) instrument which will integrate sample preparation, nucleic acid amplification, microarray hybridization and fluorescent readout in a single system. Reaching this challenging objective is possible through the combined expertise of the partners and comprises access to several selected enabling technologies: microfluidics, on-chip sample preparation, advanced microarray techniques and reading systems with ultimate sensitivity and selectivity, access to reference and field virus samples. This Bio-Micro knowledge converges in one single instrument, allowing rapid detection (less than an hour) and simultaneous identification of influenza A and B viruses (typing and sub-typing) at widespread POC with only basic skills. Furthermore, the project also aims at realizing this goal in a format that requires little supervision and is integrated in a portable compact monolithic system for deployment in the field. The consortium of 9 partners from 5 member states brings together the various expertises needed to reach these objectives, which match exactly those of the call Health 2.3.3-4: Innovative point-of-care diagnostic tests for influenza

Keywords: poc systems,diagnostics,influenza diagnostics,nucleic acid,rapid diagnostic test,influenza infection,pandemics,poc diagnostics in developped and developping countries,early biological markers
Increasing the PaRticipation of the ElDerly in Clinical Trials (PREDICT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Coordination and support actions
Countries involved: Italy,United Kingdom,Spain,Poland,Lithuania,Israel,Czechia,United Kingdom,Netherlands,United Kingdom,Romania
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-02-01
End date: 2010-07-31
Duration (months): 30.0
Total project cost (EUR): 840612.62
EU funding (EUR): 750047.0
Participants: 11
Project status: CLOSED

AIM. To investigate the reasons for the exclusion of the elderly in clinical trials and to provide solutions for this problem. INTRODUCTION. Although the elderly account for high drug consumption, they are underrepresented in clinical trials. With an increasingly ageing European population it is essential to demonstrate the efficacy and safety of drugs. Clinical trials need to take into account the relevant issues of this population, i.e. changed metabolism, multiple chronic conditions and poly-pharmacy. To examine this issue and effect a paradigm shift it is necessary to target gatekeepers and stakeholders of clinical trials. METHODS. The project will be coordinated by the Medical Economics and Research Centre, Sheffield, with guidance from the Centre for Interdisciplinary Research on Ageing at Keele University, UK. The 5 work packages (WP) will be carried out by a multi-disciplinary team of highly qualified experts in Geriatrics, Gerontology and social sciences. WP1 will involve a systematic review of the literature and review of ongoing clinical trials to assess the extent of exclusion of the elderly. Based on these findings WP2 and WP 3 will investigate why the elderly are underrepresented in clinical trials and what can be done to improve their participation. This will be carried out in 9 countries: UK, Spain, Holland, Italy, Poland, Lithuania, Romania, Israel and the Czech Republic. WP2 will research the views of health professionals and ethicists using structured questionnaires. WP3 will explore the perceptions of older patients and carers using a focus group methodology. For WP4, the recommendations from WP2 and WP3 will be used to develop a charter for the elderly in clinical trials. WP5 will disseminate and implement the findings. CONCLUSION. PREDICT will promote the inclusion of the elderly in clinical trials in Europe. This project will facilitate the improvement of the rights of older people and the quality of health care for the ageing population.

Keywords: clinical trials,elderly,geriatrics,ageism,ethics,systematic review,poly-pharmacy,qualitative research
Targeting alpha-particle emitting radionuclides to combat cancer (TARCC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,Switzerland,Germany,Germany,Sweden,Slovenia,European organisations area,Belgium,Germany
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-01-01
End date: 2011-06-30
Duration (months): 42.0
Total project cost (EUR): 4112800.2
EU funding (EUR): 3000000.0
Participants: 11
Project status: CLOSED

This project aims at improving drug delivery to cancer cells by developing targeted radiotherapy with alpha-emitting radionuclides. Alpha particles emitted by radionuclides have short tracks (about 100 microns) in body tissues. As a result, they should be most appropriate to treat small-size tumours and isolated cancer cells. This project proposes the development of improved vectors and targeting technology based on specific targeting agents (recombinant antibody fragments and synthetic peptides), pretargeting approaches and nano-colloids especially designed to deliver alpha-emitting radionuclides to cancer cells after local or systemic administration. The concept of in situ generator, that allows the use of longer half-life parents of alpha-emitting radionuclides will be developed. Several approaches to prevent the release of radionuclides after parent isotope disintegration, including encapsulation in nano-colloids, are proposed. Improved targeting methods will be tested in animal models of small-size tumours and associated dosimetry (including micro-dosimetry) and toxicity studies will be performed. The final goal of the project will be to propose one or several new products for targeted delivery of alpha-emitting radionuclides for clinical development.

Keywords: cancer,radionuclide therapy,alpha-emitting radionuclides
DIAbetes type 1 PRediction, Early Pathogenesis and Prevention (DIAPREPP)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,France,Sweden,Finland,Italy,Sweden,Spain,Germany,United Kingdom
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-04-01
End date: 2011-08-31
Duration (months): 41.0
Total project cost (EUR): 7794397.41
EU funding (EUR): 5999200.0
Participants: 12
Project status: CLOSED

The earliest currently identifiable process in the pathogenesis of type 1 diabetes (T1D) is the development of autoimmunity to islet beta cells in the form of autoantibodies. Hindering attempts to prevent autoimmune T1D, the aetiology and pathogenesis of the islet auto-immunization, including whether it is preceded by metabolic abnormalities and cell-mediated autoimmunity, is still poorly understood. To overcome this, DIAPREPP will focus on the early auto-immunization against islet antigens, in particular to disclose events preceding current autoantibody markers. The concept is that events prior to auto-immunization govern the likelihood and ‘signature’ of immunization, which in turn determines progression to disease. The overall objective is to determine mechanisms of islet autoantigen immunization. In a truly collaborative manner, and through five S/T workpackages plus three dedicated to dissemination, training, and management, DIAPREPP will 1. provide a unique set of clinical material that includes a case-control cohort representative of the world’s largest studies of pre-T1D, with follow-up and samples from birth, and pancreatic islets and lymph nodes from patients; 2. investigate the effects of environmental exposure to infections on islet cells and immune cells; 3. perform extensive metabolomic analysis of pre-autoimmune samples and in relevant animal models to test mechanistic hypotheses of auto-immunization; 4. carry out detailed analyses of early autoimmune responses with a special focus on autoreactive CD8+ T cells; and 5. apply findings to ongoing prevention studies. The expected impact of DIAPREPP is new fundamental knowledge regarding how 1. immunization against islet autoantigens can occur; 2. signs of self-immunization can be exploited for prediction and monitoring of disease; and 3. the immunization or its progression to islet beta cell destruction and T1D development can be prevented.

Keywords: islet autoimmunity,pre-autoimmunity,metabolomics,enterovirus,prevention,biobanking
A European Collaboration to optimise research for the care of cancer patients in the last days of life (OPCARE9)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Coordination and support actions
Countries involved: United Kingdom,Germany,Netherlands,Italy,Slovenia,Switzerland,Sweden,Argentina,New Zealand
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-03-01
End date: 2011-03-31
Duration (months): 37.0
Total project cost (EUR): 3224156.0
EU funding (EUR): 2224007.0
Participants: 9
Project status: CLOSED

The project aims to explore, share and collate existing knowledge and practice in each of the key themes identified within the work programme. It aims to reach consensus (based on current practice and available research evidence) on the optimum care to be delivered in the last days of life and gaps in the knowledge base. In addition, it aims to develop innovative ways of addressing gaps in knowledge with the specific aim of improving care for cancer patients in the last days of life. Clearly, such improvements would also impact positively on their informal carers and health professionals delivering the care. Importantly, it aims to do this systematically and collaboratively across Europe and beyond to integrate knowledge from a range of healthcare enviroments and cultures and to avoid duplication of resource and effort.

Keywords: cancer,care,dying,quality,needs,technologies
Evaluation of Legislation and Related Guidelines on the Procurement, Storage and Transfer of Human Tissues and Cells in the European Union – an Evidence-Based Impact Analysis (TISS.EU)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Germany,Germany,United Kingdom,Sweden,Hungary,Italy,Ireland,France,Netherlands,Lithuania
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-04-01
End date: 2011-03-31
Duration (months): 36.0
Total project cost (EUR): 894578.06
EU funding (EUR): 797672.0
Participants: 11
Project status: CLOSED

The Tiss.EU project will analyse the impact of current EU legislation and guidelines on biomedical research which is based on the procurement, storage and transfer of human tissues and cells in and across the European Union. The importance of tissue derived from the human body for biomedical research is ever increasing. In the Theme "Translating research for human health" of FP7, the EU actively encourages the networking of human sample biobank initiatives. National differences in the regulation of the handling of these tissues and cells, however, represent a serious barrier for biomedical research in the Member States and associated countries. EU legislation has dealt with these topics but covers mainly clinical application. A EU biobanking directive is still missing. This is a major handicap for translational research involving human samples. The project will evaluate the consequences of current EU legislation and related guidelines, as well as the way they are implemented at a national level, on translational research activities. It will identify regulation deficits and inconsistencies, and create an evidence base for the revision of legislation, if necessary.

Keywords: eu legislation,impact,human tissue,human cells,storage and transfer
Conservation and Divergence of Tissue-Specific Transcriptional Regulation (CONSERVREGCIRCUITRY)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Genetics,Genomics,Bioinformatics and Systems Biology
Countries involved: United Kingdom,United Kingdom
Call:  (ERC-2007-StG, 2007)
Start date: 2008-10-01
End date: 2013-09-30
Duration (months): 60.0
Total project cost (EUR): 960000.0
EU funding (EUR): 960000.0
Participants: 2
Project status: CLOSED

Vertebrates contain hundreds of different cell types which maintain phenotypic identity by a combination of epigenetic programming and genomic regulation. Systems biology approaches are now used in a number of laboratories to determine how transcription factors and chromatin marks pattern the human genome. Despite high conservation of the cellular and molecular function of many mammalian transcription factors, our recent experiments in matched mouse and human tissues indicates that most transcription factor binding events to DNA are very poorly conserved. A hypothesis that could account for this apparent divergence is that the larger regional pattern of transcription factor binding may be conserved. To test this, (1) we are characterizing the global transcriptional profile, chromatin state, and complete genomic occupancy of a set of tissue-specific transcription factors in hepatocytes of strategically chosen mammals; (2) to further identify the precise mechanistic contribution of cis and trans effects, we are comparing transcription factor binding at homologous regions of human and mouse DNA in a mouse line that carries human chromosome 21. Together, these projects will provide insight into the general principles of how transcriptional networks are evolutionarily conserved to regulate cell fate specification and function using a clinically important cell type as a model.

Keywords: systems biology genomics transcription
Fighting osteoporosis by blocking nucleotides: purinergic signalling in bone formation and homeostasis (ATPBONE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Denmark,United Kingdom,Netherlands,Italy,United Kingdom,Belgium
Call:  (FP7-HEALTH-2007-A, 2007)
Start date: 2008-01-01
End date: 2010-12-31
Duration (months): 36.0
Total project cost (EUR): 4223079.6
EU funding (EUR): 2998682.0
Participants: 7
Project status: CLOSED

Osteoporosis is a disabling disease and the incidence is expected to increase significantly over the next decades due to an increase in the elderly population. This will lead to an enormous economical burden both in the European Union and in the rest of the world. Osteoporosis should be treated early in order to prevent the bone fractures related to the disease, and a number of anti-resorptive treatments exist that can reduce the loss of bone. However, the possibilities of regaining already lost bone are limited, as only one anabolic treatment option (parathyroid hormone (PTH) )is available on the market. In most countries PTH is restricted to the most severe cases of osteoporosis with multiple fractures. Thus new anabolic treatment options for osteoporosis are highly warranted. Purinergic signalling, where nucleotides such as ATP act as extracellular signalling molecules, is a rapidly expanding field. The purinergic system has plays a central role in bone physiology, and bone deposition and resorption are finely tuned by extracellular nucleotides. Furthermore, the "purinergic system" is now believed to be one of the main transducing pathways of mechanical stimulation, a stimulus that is highly anabolic to bone. The overall aim of the proposal is to definitively prove the role of ATP and purinergic receptor signalling in the control of bone formation and homeostasis, thereby proving the potential of the system as a target for the development of new anabolic treatment regimens for osteoporosis. The aim will be addressed by examining the role of ATP as a signalling molecule in bone, the pathways and purinergic receptors involved in the signalling and their role in bone formation and homeostasis in vitro. Furthermore, translational studies in in vivo P2 receptor knock out mice will be used to show the role of the signalling pathways on bone, as well as small-scale clinical proof-of-concept studies to prove the potential of the system in targeting osteoporosis.

Keywords: osteoporosis,atp,purinergic signalling,bone formation,bone homeostasis,osteoblast,osteoclast